Unicycive CEO granted 762,200 RSUs
Gupta Shalabh K. reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Gupta Shalabh K. reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics reported that CEO Shalabh K. Gupta received a grant of 762,200 restricted stock units (RSUs) payable in common stock. These RSUs are a form of equity compensation, not an open-market purchase or sale.
According to the award terms, 105,861 shares vest immediately upon grant. An additional 21,172 shares vest over 31 months beginning on June 1, 2026, contingent on Gupta’s continued service with the company. Following this grant, the Form 4/A shows Gupta holding 762,200 RSUs linked to common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 762,200 | $0.00 | $0.00 |
Footnotes (1)
- F1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 105,861 shares vest upon grant and 21,172 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
Key Figures
Key Terms
Restricted Stock Units financial
RSU Award financial
vest upon grant financial
vest over 31 months financial
continued service financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity award did Unicycive (UNCY) grant to its CEO?
How many Unicycive RSUs vest immediately for CEO Shalabh Gupta?
What is the vesting schedule for the remaining Unicycive CEO RSUs?
Does the Unicycive CEO Form 4/A show a stock market purchase or sale?
How many Unicycive RSUs does the CEO hold after this grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.